Toyonaka, Japan

Yutaka Tomida

This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Shionogi Company Limited. Active years: 2018-2020.

USPTO Granted Patents = 3 

% Patents Active = 33.3

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Osaka, JP (2018)
  • Toyonaka, JP (2019 - 2020)

Company Filing History:


Years Active: 2018-2020

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Yutaka Tomida: Innovator in Antiviral Compounds

Introduction

Yutaka Tomida is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of antiviral research, particularly in the development of compounds that inhibit HIV replication. With a total of 3 patents to his name, Tomida's work is recognized for its potential impact on medical treatments.

Latest Patents

One of Tomida's latest patents focuses on nitrogen-containing tricyclic derivatives that exhibit HIV replication inhibitory activity. This invention presents a novel compound with antiviral properties, specifically targeting HIV. The compound is characterized by a complex formula that includes various substituents, showcasing its innovative approach to combating viral infections.

Career Highlights

Yutaka Tomida is currently associated with Shionogi Company Limited, where he continues to advance his research in antiviral compounds. His work has been instrumental in developing new medicaments that could potentially improve treatment options for HIV patients.

Collaborations

Tomida has collaborated with esteemed colleagues in his field, including Yoshinori Tamura and Shuichi Sugiyama. These partnerships have fostered a collaborative environment that enhances the research and development of innovative antiviral solutions.

Conclusion

Yutaka Tomida's contributions to antiviral research, particularly in the area of HIV, highlight his role as a significant inventor in the medical field. His ongoing work at Shionogi Company Limited continues to pave the way for advancements in treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…